Promoting Excellence in Education, Research,
and Patient Care in the Rapidly Evolving
Management of Gastrointestinal Cancer
International Society of
Gastrointestinal Oncology
isgioEstablished 2003
Save the Date for the ISGIO 2017 Conference
The 2018 Gastrointestinal Oncology Conference
The 2018 Gastrointestinal Oncology Conference, the official meeting of the International Society of Gastrointestinal Oncology, will take place November 1-2, 2018 at the Hilton Crystal City in Arlington, VA and will provide an educational forum for presenting and discussing the latest advances in the broad field of GI cancer research, as well as critical issues relevant to the care of persons with GI cancer.

Check back for registration information.
2018 Gastrointestinal Oncology Conference
Program Description
The conference will feature distinguished speakers covering a broad spectrum of topics ranging from basic science to clinical therapeutics. Presenters and discussants will explore current issues and debate controversial topics. Case presentations will be given by the faculty and the audience will participate by an interactive audience response system to stimulate discussion on diagnosis and management. This program should be of interest to professionals actively engaged clinically or scientifically in all facets of GI cancer research and care, including oncologists, surgeons, radiologists, general scientists, fellows, young investigators, nurses and pharmacists.
 
Educational Objectives
After attending this activity, the participant will demonstrate the ability to:
b Identify recent advances and innovations in the treatment of GI malignancies within the past 12 months
b Describe emerging evidence from current clinical trials that may impact treatment decision making in GI oncology
b Formulate a multi-modal approach to the treatment of hepatocellular carcinoma
b Analyze how recent clinical trial data demonstrate a significant survival benefit with a combination chemotherapy regimen in patients with metastatic pancreatic cancer
b Define which patients benefited the most based on the results of 2 large colon cancer trials demonstrated that the addition of cetuximab to chemotherapy improves outcomes for all patients with normal KRAS, regardless of BRAF status
b Discuss the multicenter trial results that demonstrate that sunitinib, a multi-targeted TKI, may delay disease progression in patients with pancreatic neuroendocrine tumors, and contribute to increased survival
b Name the prognostic value of 8 molecular markers on relapse-free survival and stages II and III colon cancer.
 
CME Accreditation and Designation Statement
Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.